Dow Jones

38 798,99

-0,22%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Aptorum Group Ltd (APM)
Aptorum Group Ltd (APM) Actualités

APM

Aptorum (APM)

Aptorum Group Ltd

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:APM

1 2 3 4 5 6 7 8 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
31/05/2024	15h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:APM	Aptorum Group Ltd
30/04/2024	15h15	Business Wire	Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update	NASDAQ:APM	Aptorum Group Ltd
06/03/2024	14h00	Business Wire	Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business	NASDAQ:APM	Aptorum Group Ltd
22/12/2023	22h30	Business Wire	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023	NASDAQ:APM	Aptorum Group Ltd
21/12/2023	22h30	Business Wire	Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders	NASDAQ:APM	Aptorum Group Ltd
21/11/2023	16h25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:APM	Aptorum Group Ltd
16/11/2023	17h00	Business Wire	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023	NASDAQ:APM	Aptorum Group Ltd
10/08/2023	08h57	Business Wire	Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets	NASDAQ:APM	Aptorum Group Ltd
22/06/2023	14h00	Business Wire	Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma	NASDAQ:APM	Aptorum Group Ltd
09/06/2023	22h31	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:APM	Aptorum Group Ltd
09/06/2023	22h30	Business Wire	Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris	NASDAQ:APM	Aptorum Group Ltd
24/05/2023	15h01	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:APM	Aptorum Group Ltd
22/05/2023	12h02	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:APM	Aptorum Group Ltd
17/05/2023	22h31	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:APM	Aptorum Group Ltd
05/05/2023	22h31	Business Wire	Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency	NASDAQ:APM	Aptorum Group Ltd
03/05/2023	15h29	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:APM	Aptorum Group Ltd
01/05/2023	14h00	Business Wire	Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited	NASDAQ:APM	Aptorum Group Ltd
28/04/2023	15h44	Business Wire	Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update	NASDAQ:APM	Aptorum Group Ltd
27/03/2023	21h30	Business Wire	Le groupe Aptorum signe une lettre d'intention et une liste de conditions pour l'acquisition d'U group	NASDAQ:APM	Aptorum Group Ltd
27/03/2023	13h00	Business Wire	Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group	NASDAQ:APM	Aptorum Group Ltd
03/03/2023	13h30	Business Wire	Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma	NASDAQ:APM	Aptorum Group Ltd
03/03/2023	13h30	Business Wire	Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus	NASDAQ:APM	Aptorum Group Ltd
02/03/2023	22h31	Edgar (US Regulatory)	Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)	NASDAQ:APM	Aptorum Group Ltd
02/03/2023	13h30	Business Wire	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China	NASDAQ:APM	Aptorum Group Ltd
10/02/2023	22h30	Business Wire	Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency	NASDAQ:APM	Aptorum Group Ltd
06/02/2023	16h08	Business Wire	Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023	NASDAQ:APM	Aptorum Group Ltd
20/01/2023	14h00	Business Wire	Aptorum Group Announces 1-for-10 Reverse Stock Split	NASDAQ:APM	Aptorum Group Ltd
17/01/2023	12h33	Edgar (US Regulatory)	Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)	NASDAQ:APM	Aptorum Group Ltd
04/01/2023	19h50	Business Wire	Aptorum Group annonce la publication d’un document co-écrit sur sa technologie PathsDx, un flux rapide de séquençage métagénomique objectif à faible profondeur pour le diagnostic des maladies infectieuses basé...	NASDAQ:APM	Aptorum Group Ltd
04/01/2023	15h00	Business Wire	Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms	NASDAQ:APM	Aptorum Group Ltd